Economic evaluation of cancer drugs : using clinical trial and real-world data / Iftekhar Khan, Ralph Crott, Zahid Bashir.
By: Khan, Iftekhar [author.].
Contributor(s): Crott, Ralph [author.] | Bashir, Zahid [author.].
Publisher: Florida : CRC, 2021Description: 416p.ISBN: 9780367727079.Subject(s): Antineoplastic agents -- Development -- Economic aspects | Clinical trials -- Economic aspects | Medical economics | Antineoplastic Agents -- economics | Clinical Trials as Topic | Drug Development -- economics | Models, Economic | Cost-Benefit Analysis | Medical economicsDDC classification: 616.99406 Summary: Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs. The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions.| Item type | Current location | Call number | Status | Date due | Barcode |
|---|---|---|---|---|---|
Books
|
NASSDOC Library | 616.99406 KHA-E (Browse shelf) | Available | 52802 |
Browsing NASSDOC Library Shelves Close shelf browser
|
No cover image available |
|
|
|
|
|
||
| 616.936209543 PAC-; Medical geography of malaria in Madhya Pradesh | 616.9792072 HIV; HIV/AIDS research in India | 616.98 DUN-E Environment and health : | 616.99406 KHA-E Economic evaluation of cancer drugs : | 618.17806 GUP-; New reproductive technologies, women's health and autonomy : freedom or dependen | 618.17806 GUP-; New reproductive technologies, women's health and autonomy : freedom or dependen | 618.4 BIR- Birthing models on the human rights frontier : |
Includes bibliographical references and index.
Cancer is a major healthcare burden across the world and impacts not only the people diagnosed with various cancers but also their families, carers, and healthcare systems. With advances in the diagnosis and treatment, more people are diagnosed early and receive treatments for a disease where few treatments options were previously available. As a result, the survival of patients with cancer has steadily improved and, in most cases, patients who are not cured may receive multiple lines of treatment, often with financial consequences for the patients, insurers and healthcare systems. Although many books exist that address economic evaluation, Economic Evaluation of Cancer Drugs using Clinical Trial and Real World Data is the first unified text that specifically addresses the economic evaluation of cancer drugs.
The authors discuss how to perform cost-effectiveness analyses while emphasising the strategic importance of designing cost-effectiveness into cancer trials and building robust economic evaluation models that have a higher chance of reimbursement if truly cost-effective. They cover the use of real-world data using cancer registries and discuss how such data can support or complement clinical trials with limited follow up. Lessons learned from failed reimbursement attempts, factors predictive of successful reimbursement and the different payer requirements across major countries including US, Australia, Canada, UK, Germany, France and Italy are also discussed. The book includes many detailed practical examples, case studies and thought-provoking exercises for use in classroom and seminar discussions.
English.
There are no comments for this item.